1
|
Ye L, Wang F, Wu H, Yuan Y, Zhang Q. Evidence of the association between asthma and lung cancer risk from mendelian randomization analysis. Sci Rep 2024; 14:23047. [PMID: 39367168 PMCID: PMC11452391 DOI: 10.1038/s41598-024-74883-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 09/30/2024] [Indexed: 10/06/2024] Open
Abstract
Asthma and lung cancer are both significant public health concerns worldwide. Previous observational studies have indicated a potential link between asthma and an increased risk of lung cancer, whereas the causal relationship remains uncertain. We aimed to investigate the potential causal relationship between asthma and lung cancer risk utilizing Mendelian randomization (MR) design.The present study employed a two-sample MR analysis utilizing summary statistics from genome-wide association studies (GWAS) with European descent of asthma and lung cancer. The MR analysis was performed using inverse variance weighting (IVW), supplemented with MR-Egger regression and weighted median method to investigate the potential causality between asthma and lung cancer. Furthermore, Sensitivity analyses were also conducted to ensure the reliability of the findings. The MR analysis showed that genetically predicted asthma had suggestive causal association with the elevated risk of lung cancer [odds ratio (OR), 1.05 (95%Cl,1.01-1.09), P = 0.01]. The consistent direction of effects observed in the three methods further supported this finding. In addition, sensitivity analyses demonstrated the reliability of the results. This study provided potential evidence supporting a causal association between asthma and lung cancer. These findings highlighted the importance of early detection and prevention strategies for lung cancer in individuals with asthma. Further research was needed to elucidate the underlying mechanisms linking asthma and lung cancer.
Collapse
Affiliation(s)
- Lingling Ye
- Department of Oncology, Nanjing Jiangning Hospital, The Affiliated Jiangning Hospital with Nanjing Medical University, 169 Hushan Road, Dongshan Street, Nanjing, 211000, Jiangsu, China
| | - Fen Wang
- Department of Oncology, Nanjing Jiangning Hospital, The Affiliated Jiangning Hospital with Nanjing Medical University, 169 Hushan Road, Dongshan Street, Nanjing, 211000, Jiangsu, China
| | - Hao Wu
- Department of Oncology, Nanjing Jiangning Hospital, The Affiliated Jiangning Hospital with Nanjing Medical University, 169 Hushan Road, Dongshan Street, Nanjing, 211000, Jiangsu, China
| | - Yihang Yuan
- Department of Oncology, Nanjing Jiangning Hospital, The Affiliated Jiangning Hospital with Nanjing Medical University, 169 Hushan Road, Dongshan Street, Nanjing, 211000, Jiangsu, China
| | - Quan'an Zhang
- Department of Oncology, Nanjing Jiangning Hospital, The Affiliated Jiangning Hospital with Nanjing Medical University, 169 Hushan Road, Dongshan Street, Nanjing, 211000, Jiangsu, China.
| |
Collapse
|
2
|
Liu H, Dong A, Rasteh AM, Wang P, Weng J. Identification of the novel exhausted T cell CD8 + markers in breast cancer. Sci Rep 2024; 14:19142. [PMID: 39160211 PMCID: PMC11333736 DOI: 10.1038/s41598-024-70184-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 08/13/2024] [Indexed: 08/21/2024] Open
Abstract
Cancer is one of the most concerning public health issues and breast cancer is one of the most common cancers in the world. The immune cells within the tumor microenvironment regulate cancer development. In this study, single immune cell data sets were used to identify marker gene sets for exhausted CD8 + T cells (CD8Tex) in breast cancer. Machine learning methods were used to cluster subtypes and establish the prognostic models with breast cancer bulk data using the gene sets to evaluate the impacts of CD8Tex. We analyzed breast cancer overexpressing and survival-associated marker genes and identified CD8Tex hub genes in the protein-protein-interaction network. The relevance of the hub genes for CD8 + T-cells in breast cancer was evaluated. The clinical associations of the hub genes were analyzed using bulk sequencing data and spatial sequencing data. The pan-cancer expression, survival, and immune association of the hub genes were analyzed. We identified biomarker gene sets for CD8Tex in breast cancer. CD8Tex-based subtyping systems and prognostic models performed well in the separation of patients with different immune relevance and survival. CRTAM, CLEC2D, and KLRB1 were identified as CD8Tex hub genes and were demonstrated to have potential clinical relevance and immune therapy impact. This study provides a unique view of the critical CD8Tex hub genes for cancer immune therapy.
Collapse
Affiliation(s)
- Hengrui Liu
- Cancer Research Institute, Jinan University, Guangzhou, China
| | | | | | - Panpan Wang
- The First Affiliated Hospital of Jinan University, Guangzhou, China.
| | - Jieling Weng
- Department of Pathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
| |
Collapse
|
3
|
Horackova K, Zemankova P, Nehasil P, Vocka M, Hovhannisyan M, Matejkova K, Janatova M, Cerna M, Kleiblova P, Jelinkova S, Stastna B, Just P, Dolezalova T, Nemcova B, Urbanova M, Koudova M, Hazova J, Machackova E, Foretova L, Stranecky V, Zikan M, Kleibl Z, Soukupova J. A comprehensive analysis of germline predisposition to early-onset ovarian cancer. Sci Rep 2024; 14:16183. [PMID: 39003285 PMCID: PMC11246516 DOI: 10.1038/s41598-024-66324-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Accepted: 07/01/2024] [Indexed: 07/15/2024] Open
Abstract
The subset of ovarian cancer (OC) diagnosed ≤ 30yo represents a distinct subgroup exhibiting disparities from late-onset OC in many aspects, including indefinite germline cancer predisposition. We performed DNA/RNA-WES with HLA-typing, PRS assessment and survival analysis in 123 early-onset OC-patients compared to histology/stage-matched late-onset and unselected OC-patients, and population-matched controls. Only 6/123(4.9%) early-onset OC-patients carried a germline pathogenic variant (GPV) in high-penetrance OC-predisposition genes. Nevertheless, our comprehensive germline analysis of early-onset OC-patients revealed two divergent trajectories of potential germline susceptibility. Firstly, overrepresentation analysis highlighted a connection to breast cancer (BC) that was supported by the CHEK2 GPV enrichment in early-onset OC(p = 1.2 × 10-4), and the presumably BC-specific PRS313, which successfully stratified early-onset OC-patients from controls(p = 0.03). The second avenue pointed towards the impaired immune response, indicated by LY75-CD302 GPV(p = 8.3 × 10-4) and diminished HLA diversity compared with controls(p = 3 × 10-7). Furthermore, we found a significantly higher overall GPV burden in early-onset OC-patients compared to controls(p = 3.8 × 10-4). The genetic predisposition to early-onset OC appears to be a heterogeneous and complex process that goes beyond the traditional Mendelian monogenic understanding of hereditary cancer predisposition, with a significant role of the immune system. We speculate that rather a cumulative overall GPV burden than specific GPV may potentially increase OC risk, concomitantly with reduced HLA diversity.
Collapse
Grants
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-09-00355 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-09-00355 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- RVO-VFN 00064165 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- NU20-03-00016 Ministerstvo Zdravotnictví Ceské Republiky
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- SVV260631 Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- COOPERATIO Univerzita Karlova v Praze
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- The National Center for Medical Genomics (LM2023067) Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
- LX22NPO05102 Ministerstvo Školství, Mládeže a Tělovýchovy
Collapse
Affiliation(s)
- Klara Horackova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Petra Zemankova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Petr Nehasil
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Michal Vocka
- Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Milena Hovhannisyan
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Katerina Matejkova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic
| | - Marketa Janatova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Marta Cerna
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Petra Kleiblova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Sandra Jelinkova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Barbora Stastna
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
| | - Pavel Just
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Tatana Dolezalova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Barbora Nemcova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Marketa Urbanova
- Centre for Medical Genetics and Reproductive Medicine, GENNET, Prague, Czech Republic
| | - Monika Koudova
- Centre for Medical Genetics and Reproductive Medicine, GENNET, Prague, Czech Republic
| | - Jana Hazova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Eva Machackova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Lenka Foretova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Viktor Stranecky
- Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Michal Zikan
- Department of Gynecology and Obstetrics, Bulovka University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Zdenek Kleibl
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jana Soukupova
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
| |
Collapse
|
4
|
Tizu M, Calenic B, Hârza M, Cristea BM, Maruntelu I, Caragea AM, Talangescu A, Dima A, Constantinescu AE, Constantinescu I. HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia. Genet Res (Camb) 2024; 2024:8852876. [PMID: 38449839 PMCID: PMC10917483 DOI: 10.1155/2024/8852876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 07/24/2023] [Accepted: 02/21/2024] [Indexed: 03/08/2024] Open
Abstract
Materials and Methods This study included 66 patients with CLL, diagnosed between 2020 and 2022, and 100 healthy controls. HLA class I and class II genes (HLA-A/B/C, HLA-DQA1/DQB1/DPA1/DPB1, and HLA-DRB1/3/4/5) were investigated using next-generation sequencing technology. Results Several HLA alleles were strongly associated with CLL. The most important finding was that HLA-DRB1∗04:02:01 (p=0.001, OR = 1.05) and HLA-DRB3∗02:01:01 (p=0.009, OR = 1.03) have a predisposing role in CLL development. Moreover, we identified that HLA-A∗24:02:01 0.01 (p=0.01, OR = 0.38), HLA-DQA1∗05:05:01 (p=0.01, OR = 0.56), HLA-DQB1∗03:02:01 (p=0.03, OR = 0.40), and HLA-DRB4∗01:03:01 (p=0.03, OR = 0.54 alleles have protective roles. Correlations between HLA expression and gender showed that women had a higher expression of protective HLA alleles when compared to men. Conclusions Our data are the first to indicate that in Romanian patients with CLL, the HLA-A∗24:02:01 and HLA-DQA1∗05:05:01 alleles have a protective role against CLL development, whereas HLA-DRB1∗04:02:01 and HLA-DRB3∗02:01:01alleles are positively associated with CLL.
Collapse
Affiliation(s)
- Maria Tizu
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Bogdan Calenic
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Mihai Hârza
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Bogdan M. Cristea
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Ion Maruntelu
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Andreea M. Caragea
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Adriana Talangescu
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Alina Dima
- Colentina Clinical Hospital, Rheumatology Department Bucharest, 19-21 Stefan Cel Mare Street, Bucharest 020125, Romania
| | - Alexandra E. Constantinescu
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
| | - Ileana Constantinescu
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, Bucharest 022328, Romania
| |
Collapse
|
5
|
Ivanova M, Ormandjieva A, Dodova R, Kaneva R, Shivarov V. Possible impact of HLA class I and class II on malignancies driven by a single germ-line BRCA1 mutation. Int J Immunogenet 2023; 50:243-248. [PMID: 37505908 DOI: 10.1111/iji.12631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 07/13/2023] [Accepted: 07/21/2023] [Indexed: 07/30/2023]
Abstract
This study provides the first immunogenetic preliminary evidence that specific human leucocyte antigen (HLA) class I and class II alleles and haplotypes may be relevant for BRCA1 c.5263_5264insC driven oncogenesis. Observed HLA associations might have practical implications for establishment of predictive markers for the response to immunotherapies in malignancies driven by this germ-line mutation.
Collapse
Affiliation(s)
- Milena Ivanova
- Department of Clinical Immunology, University Hospital Alexandrovska, Medical University Sofia, Sofia, Bulgaria
| | - Anastasia Ormandjieva
- Department of Clinical Immunology, University Hospital Alexandrovska, Medical University Sofia, Sofia, Bulgaria
| | - Rumyana Dodova
- Center for Molecular Medicine, Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University Sofia, Sofia, Bulgaria
| | - Radka Kaneva
- Center for Molecular Medicine, Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University Sofia, Sofia, Bulgaria
| | - Velizar Shivarov
- Department of Experimental Research, Medical University Pleven, Pleven, Bulgaria
| |
Collapse
|
6
|
Khan T, Ledoux IM, Aziz F, Al Ali F, Chin-Smith E, Ata M, Karim MY, Marr N. Associations between HLA class II alleles and IgE sensitization to allergens in the Qatar Biobank cohort. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. GLOBAL 2023; 2:100117. [PMID: 37779520 PMCID: PMC10509938 DOI: 10.1016/j.jacig.2023.100117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 01/16/2023] [Accepted: 02/05/2023] [Indexed: 10/03/2023]
Abstract
Background Allergic disorders are the consequence of IgE sensitization to allergens. Population studies have shown that certain human leukocyte antigen (HLA) alleles are associated with increased or decreased risk of developing allergy. Objective We aimed to characterize the relationship between HLA class II allelic diversity and IgE sensitization in an understudied Arab population. Methods We explored associations between IgE sensitization to 7 allergen mixes and mesquite (comprising 41 food or aeroallergens) and 45 common classical HLA class II alleles in a well-defined cohort of 797 individuals representing the general adult population of Qatari nationals and long-term residents. To do so, we performed HLA calling from whole genome sequencing data at 2-field resolution using 2 independent algorithms. We then applied 3 different regression models to assess either each allergen mix independently, in the context of IgE sensitization to other allergens tested, or polysensitization. Results More than half (n = 447) of the study participants showed IgE sensitization to at least 1 allergen, most of them (n = 400) to aeroallergens (Phadiatop). We identified statistically significant negative and positive associations with 24 HLA class II alleles. These have been reported to confer risk or protection from variety of diseases; however, only a few have previously been associated with allergy in other populations. Conclusions Our study reveals several new risk and protective genetic markers for allergen-specific IgE sensitization. This is a first and essential step toward a better understanding of the origins of allergic diseases in this understudied population.
Collapse
Affiliation(s)
- Taushif Khan
- Department of Human Immunology, Sidra Medicine, Doha, Qatar
- Department of Computational Science, The Jackson Laboratory, Farmington, Conn
| | | | - Ferdousey Aziz
- the Department of Pathology, Sidra Medicine, Doha, Qatar
| | - Fatima Al Ali
- Department of Human Immunology, Sidra Medicine, Doha, Qatar
| | | | - Manar Ata
- Department of Human Immunology, Sidra Medicine, Doha, Qatar
| | - Mohammed Yousuf Karim
- the Department of Pathology, Sidra Medicine, Doha, Qatar
- the College of Medicine, Qatar University, Doha, Qatar
| | - Nico Marr
- Department of Human Immunology, Sidra Medicine, Doha, Qatar
- the College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
- Institute of Translational Immunology, Brandenburg Medical School, Brandenburg an der Havel, Germany
| |
Collapse
|
7
|
Witt J, Haupt S, Ahadova A, Bohaumilitzky L, Fuchs V, Ballhausen A, Przybilla MJ, Jendrusch M, Seppälä TT, Fürst D, Walle T, Busch E, Haag GM, Hüneburg R, Nattermann J, von Knebel Doeberitz M, Heuveline V, Kloor M. A simple approach for detecting HLA-A*02 alleles in archival formalin-fixed paraffin-embedded tissue samples and an application example for studying cancer immunoediting. HLA 2023; 101:24-33. [PMID: 36251018 DOI: 10.1111/tan.14846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 09/05/2022] [Accepted: 10/07/2022] [Indexed: 12/13/2022]
Abstract
The HLA system represents a central component of the antigen presentation machinery. As every patient possesses a defined set of HLA molecules, only certain antigens can be presented on the cell surface. Thus, studying HLA type-dependent antigen presentation can improve the understanding of variation in susceptibility to various diseases, including infectious diseases and cancer. In archival formalin-fixed paraffin-embedded (FFPE) tissue, the HLA type is difficult to analyze because of fragmentation of DNA, hindering the application of commonly used assays that rely on long DNA stretches. Addressing these difficulties, we present a refined approach for characterizing presence or absence of HLA-A*02, the most common HLA-A allele in the Caucasian population, in archival samples. We validated our genotyping strategy in a cohort of 90 samples with HLA status obtained by an NGS-based method. 90% (n = 81) of the samples could be analyzed with the approach. For all of them, the presence or absence of HLA-A*02 alleles was correctly determined with the method, demonstrating 100% sensitivity and specificity (95% CI: 91.40%-100% and 91.19%-100%). Furthermore, we provide an example of application in an independent cohort of 73 FFPE microsatellite-unstable (MSI) colorectal cancer samples. As MSI cancer cells encompass a high number of mutations in coding microsatellites, leading to the generation of highly immunogenic frameshift peptide antigens, they are ideally suited for studying relations between the mutational landscape of tumor cells and interindividual differences in the immune system, including the HLA genotype. Overall, our method can help to promote studying HLA type-dependency during the pathogenesis of a wide range of diseases, making archival and historic tissue samples accessible for identifying HLA-A*02 alleles.
Collapse
Affiliation(s)
- Johannes Witt
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Saskia Haupt
- Engineering Mathematics and Computing Lab, Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany.,Data Mining and Uncertainty Quantification (DMQ), Heidelberg Institute for Theoretical Studies, Heidelberg, Germany
| | - Aysel Ahadova
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Lena Bohaumilitzky
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Vera Fuchs
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Alexej Ballhausen
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Hematology, Oncology and Tumor Immunology, Charité -Universitätsmedizin Berlin, Berlin, Germany
| | - Moritz Jakob Przybilla
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael Jendrusch
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Toni T Seppälä
- Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.,Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.,Department of Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland.,Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland
| | - Daniel Fürst
- Department of Transplantation Immunology, Institute of clinical Transfusion Medicine and Immune Genetics, Ulm, Germany
| | - Thomas Walle
- Department of Medical Oncology, National Centre for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Elena Busch
- Department of Medical Oncology, National Centre for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Georg Martin Haag
- Department of Medical Oncology, National Centre for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Robert Hüneburg
- Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.,National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany
| | - Jacob Nattermann
- Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.,National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany
| | - Magnus von Knebel Doeberitz
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Vincent Heuveline
- Engineering Mathematics and Computing Lab, Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany.,Data Mining and Uncertainty Quantification (DMQ), Heidelberg Institute for Theoretical Studies, Heidelberg, Germany
| | - Matthias Kloor
- Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
8
|
Ho PJ, Khng AJ, Tan BKT, Tan EY, Tan SM, Tan VKM, Lim GH, Aronson KJ, Chan TL, Choi JY, Dennis J, Ho WK, Hou MF, Ito H, Iwasaki M, John EM, Kang D, Kim SW, Kurian AW, Kwong A, Lophatananon A, Matsuo K, Mohd-Taib NA, Muir K, Murphy RA, Park SK, Shen CY, Shu XO, Teo SH, Wang Q, Yamaji T, Zheng W, Bolla MK, Dunning AM, Easton DF, Pharoah PDP, Hartman M, Li J. Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer 2022; 29:869-879. [PMID: 35543923 PMCID: PMC9385763 DOI: 10.1007/s12282-022-01366-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Accepted: 04/22/2022] [Indexed: 11/24/2022]
Abstract
BACKGROUND Human leukocyte antigen (HLA) genes play critical roles in immune surveillance, an important defence against tumors. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. We investigate the relevance of the major histocompatibility complex region in breast cancer susceptibility, using imputed class I and II HLA alleles, in 25,484 women of Asian ancestry. METHODS A total of 12,901 breast cancer cases and 12,583 controls from 12 case-control studies were included in our pooled analysis. HLA imputation was performed using SNP2HLA on 10,886 quality-controlled variants within the 15-55 Mb region on chromosome 6. HLA alleles (n = 175) with info scores greater than 0.8 and frequencies greater than 0.01 were included (resolution at two-digit level: 71; four-digit level: 104). We studied the associations between HLA alleles and breast cancer risk using logistic regression, adjusting for population structure and age. Associations between HLA alleles and the risk of subtypes of breast cancer (ER-positive, ER-negative, HER2-positive, HER2-negative, early-stage, and late-stage) were examined. RESULTS We did not observe associations between any HLA allele and breast cancer risk at P < 5e-8; the smallest p value was observed for HLA-C*12:03 (OR = 1.29, P = 1.08e-3). Ninety-five percent of the effect sizes (OR) observed were between 0.90 and 1.23. Similar results were observed when different subtypes of breast cancer were studied (95% of ORs were between 0.85 and 1.18). CONCLUSIONS No imputed HLA allele was associated with breast cancer risk in our large Asian study. Direct measurement of HLA gene expressions may be required to further explore the associations between HLA genes and breast cancer risk.
Collapse
Affiliation(s)
- Peh Joo Ho
- Women’s Health and Genetics, Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore, 138672 Singapore
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, 119077 Singapore
- Department of Surgery, National University Health System, Singapore, 119228 Singapore
| | - Alexis Jiaying Khng
- Women’s Health and Genetics, Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore, 138672 Singapore
| | - Benita Kiat-Tee Tan
- Department of Breast Surgery, Singapore General Hospital, Singapore, Singapore
- Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore
- Department of General Surgery, Sengkang General Hospital, Singapore, Singapore
| | - Ern Yu Tan
- Department of General Surgery, Tan Tock Seng Hospital, Singapore, 308433 Singapore
- Lee Kong Chian School of Medicine, Singapore, Singapore
- Institute of Molecular and Cell Biology, Singapore, Singapore
| | - Su-Ming Tan
- Division of Breast Surgery, Changi General Hospital, Singapore, Singapore
| | - Veronique Kiak Mien Tan
- Department of Breast Surgery, Singapore General Hospital, Singapore, Singapore
- Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore
| | - Geok Hoon Lim
- KK Breast Department, KK Women’s and Children’s Hospital, Singapore, 229899 Singapore
| | - Kristan J. Aronson
- Department of Public Health Sciences, and Cancer Research Institute, Queen’s University, Kingston, ON K7L 3N6 Canada
| | - Tsun L. Chan
- Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, Hong Kong
- Department of Molecular Pathology, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong
| | - Ji-Yeob Choi
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, 03080 Korea
- Cancer Research Institute, Seoul National University, Seoul, 03080 Korea
- Institute of Health Policy and Management, Seoul National University Medical Research Center, Seoul, 03080 Korea
| | - Joe Dennis
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
| | - Weang-Kee Ho
- Department of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor Malaysia
- Breast Cancer Research Programme, Cancer Research Malaysia, 47500 Subang Jaya, Selangor Malaysia
| | - Ming-Feng Hou
- Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital, Kao-hsiung, 812 Taiwan
| | - Hidemi Ito
- Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, 464-8681 Japan
- Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550 Japan
| | - Motoki Iwasaki
- Division of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, 104-0045 Japan
| | - Esther M. John
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA 94305 USA
- Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304 USA
| | - Daehee Kang
- Cancer Research Institute, Seoul National University, Seoul, 03080 Korea
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, 03080 Korea
| | - Sung-Won Kim
- Department of Surgery, Daerim Saint Mary’s Hospital, Seoul, 07442 Korea
| | - Allison W. Kurian
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA 94305 USA
- Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304 USA
| | - Ava Kwong
- Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, Hong Kong
- Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
- Department of Surgery and Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong
| | - Artitaya Lophatananon
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL UK
| | - Keitaro Matsuo
- Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550 Japan
- Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, 464-8681 Japan
| | - Nur Aishah Mohd-Taib
- Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
| | - Kenneth Muir
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL UK
| | - Rachel A. Murphy
- School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z4 Canada
- Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3 Canada
| | - Sue K. Park
- Cancer Research Institute, Seoul National University, Seoul, 03080 Korea
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, 03080 Korea
- Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, 03080 South Korea
| | - Chen-Yang Shen
- Institute of Biomedical Sciences, Academia Sinica, Taipei, 115 Taiwan
- School of Public Health, China Medical University, Taichung, Taiwan
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 USA
| | - Soo Hwang Teo
- Breast Cancer Research Programme, Cancer Research Malaysia, 47500 Subang Jaya, Selangor Malaysia
- Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
| | - Qin Wang
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
| | - Taiki Yamaji
- Division of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, 104-0045 Japan
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 USA
| | - Manjeet K. Bolla
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
| | - Alison M. Dunning
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
| | - Douglas F. Easton
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
| | - Paul D. P. Pharoah
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN UK
| | - Mikael Hartman
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, 119077 Singapore
- Department of Surgery, National University Health System, Singapore, 119228 Singapore
| | - Jingmei Li
- Women’s Health and Genetics, Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore, 138672 Singapore
- Department of Surgery, National University Health System, Singapore, 119228 Singapore
| |
Collapse
|
9
|
Zouré AA, Amegnona LJ, Zongo N, Kiendrebeogo IT, Sorgho PA, Zongo FI, Yonli AT, Sombié HK, Bambara AH, Sawadogo AY, Ouedraogo MNL, Traoré L, Zongo SV, Lallogo DT, Bazié BVJTE, Zohoncon TM, Dijgma FW, Simpore J. Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso. Open Life Sci 2021; 16:1101-1110. [PMID: 34712820 PMCID: PMC8511965 DOI: 10.1515/biol-2021-0113] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 07/28/2021] [Accepted: 08/16/2021] [Indexed: 01/20/2023] Open
Abstract
Several factors contribute to the development of breast cancer, including the immune system. This study is aimed to characterize the carriage of human leukocyte antigen (HLA)-DRB1*11 and 1*12 alleles in patients with breast cancer. This case-control study consisted of 96 histologically diagnosed breast cancer cases and 102 controls (cases without breast abnormalities). A multiplex polymerase chain reaction (PCR) was used to characterize the carriage of HLA-DRB1*11 and 1*12 alleles. The HLA-DRB1*11 allele was present in 26.59% of cases and 22.55% of controls. The HLA-DRB1*12 allele was present in 56.63% of cases and 55.88% of controls. This study found no direct association between the carriage of the HLA-DRB1*11 and HLA-DRB1*12 alleles and the occurrence of breast cancer. In addition, the deletion of the HLA-DRB1*11 allele is associated (beneficial effect) with obesity/overweight (OR = 0.13; 95% CI [0.01-1.14]; and p = 0.03) which is a risk for breast cancer. No direct association was found between the carriage of HLA-DRB1*11 and 1*12 alleles and breast cancer risk. However, further investigation of other HLA alleles involved in the occurrence of breast cancer may provide more information.
Collapse
Affiliation(s)
- Abdou Azaque Zouré
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
- Department of Biomedical and Public Health/Institute of Health Sciences Research, (IRSS/CNRST), Institute of Health Sciences Research, 03 BP 7192, Ouagadougou 03, Burkina Faso
| | - Lanyo Jospin Amegnona
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Nayi Zongo
- Department of Surgery and Surgical Specialties, Service of General and Digestive Surgery, University Hospital Centre-Yalgado OUEDRAOGO, UFR/SDS, University Joseph KI-ZERBO, 03 BP 7021, Ouagadougou 03, Burkina Faso
| | - Isabelle Touwendpoulimdé Kiendrebeogo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Pegdwendé Abel Sorgho
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Fabienne Ingrid Zongo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Albert Théophane Yonli
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Herman Karim Sombié
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Aboubacar Hierrhum Bambara
- Department of Medicine and Medical Specialties, Service of Oncology, University Hospital Centre-BOGODOGO, University Joseph KI-ZERBO, UFR/SDS, 03 BP 7021, Ouagadougou 03, Burkina Faso
| | - Alexis Yobi Sawadogo
- Department of Gynecology-Obstetrics, Service of Gynecology, University Hospital Centre-BOGODOGO, University Joseph KI ZERBO, UFR/SDS, 03 BP 7021, Ouagadougou 03, Burkina Faso
| | - Marie N. L. Ouedraogo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
- Faculty of Medicine, University Saint Thomas d’Aquin, 06 BP 10212, Ouagadougou 01, Burkina Faso
| | - Lassina Traoré
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Sidnooma Véronique Zongo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Doriane Tatiana Lallogo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Bapio Valery Jean Télesphore Elvira Bazié
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Théodora M. Zohoncon
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
- Faculty of Medicine, University Saint Thomas d’Aquin, 06 BP 10212, Ouagadougou 01, Burkina Faso
| | - Florencia W. Dijgma
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Jacques Simpore
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| |
Collapse
|